Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment

References

• JarboeJGuptaASaifWTherapeutic human monoclonal antibodies against cancerMethods Mol Biol20141060617724037836
   PubMedGoogle Scholar
• ZipfelPFSkerkaCComplement regulators and inhibitory proteinsNat Rev Immunol200991072974019730437
   PubMed Web of Science ®Google Scholar
• ClynesRATowersTLPrestaLGRavetchJVInhibitory Fc receptors modulate in vivo cytotoxicity against tumor targetsNat Med20006444344610742152
   PubMed Web of Science ®Google Scholar
• ManchesOLuiGChaperotLIn vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomasBlood2003101394995412393572
   PubMed Web of Science ®Google Scholar
• ArnouldLGellyMPenault-LlorcaFTrastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?Br J Cancer200694225926716404427
   PubMed Web of Science ®Google Scholar
• WeinerLMSuranaRWangSMonoclonal antibodies: versatile platforms for cancer immunotherapyNat Rev Immunol201010531732720414205
   PubMed Web of Science ®Google Scholar
• TophamNJHewittEWNatural killer cell cytotoxicity: how do they pull the trigger?Immunology2009128171519689731
   PubMed Web of Science ®Google Scholar
• CassatellaMAAnegónICuturiMCGriskeyPTrinchieriGPerussiaBFc gamma R(CD16) interaction with ligand induces Ca2+ mobilization and phosphoinositide turnover in human natural killer cells. Role of Ca2+ in Fc gamma R(CD16)-induced transcription and expression of lymphokine genesJ Exp Med198916925495672536067
   PubMed Web of Science ®Google Scholar
• SicaADormanLViggianoVInteraction of NF-kappaB and NFAT with the interferon-gamma promoterJ Biol Chem19972724830412304209374532
   PubMed Web of Science ®Google Scholar
• AldersonKLSondelPMClinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicityJ Biomed Biotechnol2011201137912321660134
   PubMedGoogle Scholar
• RavetchJVBollandSIgG Fc receptorsAnnu Rev Immunol20011927529011244038
   PubMed Web of Science ®Google Scholar
• TakaiTRoles of Fc receptors in autoimmunityNat Rev Immunol20022858059212154377
   PubMed Web of Science ®Google Scholar
• NimmerjahnFRavetchJVFcgamma receptors as regulators of immune responsesNat Rev Immunol200881344718064051
   PubMed Web of Science ®Google Scholar
• RobertsonMJCaligiuriMAManleyTJLevineHRitzJHuman natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysisJ Immunol199014510319432011700001
   PubMed Web of Science ®Google Scholar
• WalzerTJaegerSChaixJVivierENatural killer cells: from CD3(−) NKp46(+) to post-genomics meta-analysesCurr Opin Immunol200719336537217442558
   PubMed Web of Science ®Google Scholar
• PenackOGentiliniCFischerLCD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targetsLeukemia200519583584015744340
   PubMed Web of Science ®Google Scholar
• StabileHNistiPMorroneSMultifunctional human CD56low CD16low natural killer cells are the prominent subset in bone marrow of both pediatric healthy donors and leukemic patientsHaematologica Epub1162015
   Web of Science ®Google Scholar
• PegramHJAndrewsDMSmythMJDarcyPKKershawMHActivating and inhibitory receptors of natural killer cellsImmunol Cell Biol201189221622420567250
   PubMed Web of Science ®Google Scholar
• CartronGDacheuxLSallesGTherapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa geneBlood200299375475811806974
   PubMed Web of Science ®Google Scholar
• WengWKLevyRTwo immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphomaJ Clin Oncol200321213940394712975461
   PubMed Web of Science ®Google Scholar
• AddeoRCaragliaMCerboneDPanitumumab: a new frontier of target therapy for the treatment of metastatic colorectal cancerExpert Rev Anticancer Ther201010449950520397915
   PubMed Web of Science ®Google Scholar
• KennedyBHillmenPImmunological effects and safe administration of alemtuzumab (MabCampath) in advanced B-cLLMed Oncol200219SupplS49S5512180492
   PubMed Web of Science ®Google Scholar
• HudisCATrastuzumab–mechanism of action and use in clinical practiceN Engl J Med20073571395117611206
   PubMed Web of Science ®Google Scholar
• KoeneHRKleijerMAlgraJRoosDvon dem BorneAEde HaasMFc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotypeBlood1997903110911149242542
   PubMed Web of Science ®Google Scholar
• WuJEdbergJCRedechaPBA novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune diseaseJ Clin Invest19971005105910709276722
   PubMed Web of Science ®Google Scholar
• PerskyDODornanDGoldmanBHFc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy aloneHaematologica201297693794222271896
   PubMed Web of Science ®Google Scholar
• RodríguezJZarateRBandresEFc gamma receptor polymorphisms as predictive markers of cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancerEur J Cancer201248121774178022305465
   PubMed Web of Science ®Google Scholar
• WalshGJefferisRPost-translational modifications in the context of therapeutic proteinsNat Biotechnol200624101241125217033665
   PubMed Web of Science ®Google Scholar
• WrightAMorrisonSLEffect of glycosylation on antibody function: implications for genetic engineeringTrends Biotechnol199715126329032990
   PubMed Web of Science ®Google Scholar
• PeippMLammerts van BuerenJJSchneider-MerckTAntibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cellsBlood200811262390239918566325
   PubMed Web of Science ®Google Scholar
• SchusterMUmanaPFerraraCImproved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineeringCancer Res200565177934794116140965
   PubMed Web of Science ®Google Scholar
• StavenhagenJBGorlatovSTuaillonNFc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptorsCancer Res200767188882889017875730
   PubMed Web of Science ®Google Scholar
• RafiqSSiadakAButcharJPGlycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignanciesMAbs20135572373523883821
   PubMed Web of Science ®Google Scholar
• GoedeVFischerKBuschRObinutuzumab plus chlorambucil in patients with CLL and coexisting conditionsN Engl J Med2014370121101111024401022
   PubMed Web of Science ®Google Scholar
• MössnerEBrünkerPMoserSIncreasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicityBlood2010115224393440220194898
   PubMed Web of Science ®Google Scholar
• PatzMIsaevaPForcobNComparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cellsBr J Haematol2011152329530621155758
   PubMed Web of Science ®Google Scholar
• LazarGADangWKarkiSEngineered antibody Fc variants with enhanced effector functionProc Natl Acad Sci U S A2006103114005401016537476
   PubMed Web of Science ®Google Scholar
• BenenciaFCourrègesMCConejo-GarcíaJRHSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancerMol Ther200512578980215925544
   PubMed Web of Science ®Google Scholar
• TodaMRabkinSDKojimaHMartuzaRLHerpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunityHum Gene Ther199910338539310048391
   PubMed Web of Science ®Google Scholar
• LiHDutuorAFuXZhangXInduction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor modelJ Gene Med20079316116917266169
   PubMed Web of Science ®Google Scholar
• LiHDutuorATaoLFuXZhangXVirotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastomaClin Cancer Res200713131632217200370
   PubMed Web of Science ®Google Scholar
• MillerCGFraserNWRequirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma modelMol Ther20037674174712788647
   PubMed Web of Science ®Google Scholar
• PrestwichRJErringtonFIlettEJTumor infection by oncolytic reovirus primes adaptive antitumor immunityClin Cancer Res200814227358736619010851
   PubMed Web of Science ®Google Scholar
• AghiMMartuzaRLOncolytic viral therapies – the clinical experienceOncogene200524527802781616299539
   PubMed Web of Science ®Google Scholar
• PatelMRKratzkeRAOncolytic virus therapy for cancer: the first wave of translational clinical trialsTransl Res2013161435536423313629
   PubMed Web of Science ®Google Scholar
• SeymourLWCawoodRFisherKDCellular carriers or free viruses?Curr Opin Mol Ther200810432132218683095
   PubMedGoogle Scholar
• FieldsBNKnipeDMHowleyPMFields Virology3rd edPhiladelphia, PALippincott-Raven Publishers1996
   Google Scholar
• CoffeyMCStrongJEForsythPALeePWReovirus therapy of tumors with activated Ras pathwayScience19982825392133213349812900
   PubMed Web of Science ®Google Scholar
• MarcatoPShmulevitzMLeePWConnecting reovirus oncolysis and Ras signalingCell Cycle20054455655915753655
   PubMed Web of Science ®Google Scholar
• MarcatoPShmulevitzMPanDStoltzDLeePWRas transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent releaseMol Ther20071581522153017457318
   PubMed Web of Science ®Google Scholar
• ShmulevitzMMarcatoPLeePWUnshackling the links between reovirus oncolysis, Ras signaling, translational control and cancerOncogene200524527720772816299532
   PubMed Web of Science ®Google Scholar
• ShmulevitzMMarcatoPLeePWActivated Ras signaling significantly enhances reovirus replication and spreadCancer Gene Ther2010171697019590528
   PubMed Web of Science ®Google Scholar
• ShmulevitzMPanLZGarantKPanDLeePWOncogenic Ras promotes reovirus spread by suppressing IFN-beta production through negative regulation of RIG-I signalingCancer Res201070124912492120501842
   PubMed Web of Science ®Google Scholar
• PrestwichRJHarringtonKJPandhaHSVileRGMelcherAAErringtonFOncolytic viruses: a novel form of immunotherapyExpert Rev Anticancer Ther20088101581158818925850
   PubMed Web of Science ®Google Scholar
• GujarSAMarcatoPPanDLeePWReovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunityMol Cancer Ther20109112924293320978162
   PubMed Web of Science ®Google Scholar
• PrestwichRJIlettEJErringtonFImmune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replicationClin Cancer Res200915134374438119509134
   PubMed Web of Science ®Google Scholar
• GujarSAPanDAMarcatoPGarantKALeePWOncolytic virus-initiated protective immunity against prostate cancerMol Ther201119479780421245852
   PubMed Web of Science ®Google Scholar
• ErringtonFWhiteCLTwiggerKRInflammatory tumour cell killing by oncolytic reovirus for the treatment of melanomaGene Ther200815181257127018401435
   PubMed Web of Science ®Google Scholar
• HataYEtohTInomataMShiraishiNNishizonoAKitanoSEfficacy of oncolytic reovirus against human breast cancer cellsOncol Rep20081961395139818497942
   PubMed Web of Science ®Google Scholar
• HirasawaKNishikawaSGNormanKLAlainTKossakowskaALeePWOncolytic reovirus against ovarian and colon cancerCancer Res20026261696170111912142
   PubMed Web of Science ®Google Scholar
• AlainTHirasawaKPonKJReovirus therapy of lymphoid malignanciesBlood2002100124146415312393565
   PubMed Web of Science ®Google Scholar
• PrestwichRJErringtonFSteeleLPReciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirusJ Immunol200918374312432119734207
   PubMed Web of Science ®Google Scholar
• ErringtonFSteeleLPrestwichRReovirus activates human dendritic cells to promote innate antitumor immunityJ Immunol200818096018602618424722
   PubMed Web of Science ®Google Scholar
• HamanoSMoriYAoyamaMOncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cellsCancer Lett20153562 Pt B84685425444894
   PubMed Web of Science ®Google Scholar
• AdairRARoulstoneVScottKJCell carriage, delivery, and selective replication of an oncolytic virus in tumor in patientsSci Transl Med20124138138ra77
   Web of Science ®Google Scholar
• AdairRAScottKJFraserSCytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cellsInt J Cancer2013132102327233823114986
   PubMed Web of Science ®Google Scholar
• KicielinskiKPChioccaEAYuJSGillGMCoffeyMMarkertJMPhase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adultsMol Ther20142251056106224553100
   PubMed Web of Science ®Google Scholar
• ForsythPRoldánGGeorgeDA phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomasMol Ther200816362763218253152
   PubMed Web of Science ®Google Scholar
• GollamudiRGhalibMHDesaiKKIntravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumorsInvest New Drugs201028564164919572105
   PubMed Web of Science ®Google Scholar
• MorrisDGFengXDiFrancescoLMREO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumorsInvest New Drugs201331369670622886613
   PubMed Web of Science ®Google Scholar
• GalanisEMarkovicSNSumanVJPhase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanomaMol Ther201220101998200322871663
   PubMed Web of Science ®Google Scholar
• VidalLPandhaHSYapTAA phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancerClin Cancer Res200814217127713718981012
   PubMed Web of Science ®Google Scholar
• HarringtonKJKarapanagiotouEMRoulstoneVTwo-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancersClin Cancer Res201016113067307720484020
   PubMed Web of Science ®Google Scholar
• KarapanagiotouEMRoulstoneVTwiggerKPhase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignanciesClin Cancer Res20121872080208922316603
   PubMed Web of Science ®Google Scholar
• CominsCSpicerJProtheroeAREO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancerClin Cancer Res201016225564557220926400
   PubMed Web of Science ®Google Scholar
• JegoGBatailleRGeffroy-LuseauADescampsGPellat-DeceunynckCPathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptorsLeukemia20062061130113716628189
   PubMed Web of Science ®Google Scholar
• TakedaKKaishoTAkiraSToll-like receptorsAnnu Rev Immunol20032133537612524386
   PubMed Web of Science ®Google Scholar
• LuHTLR agonists for cancer immunotherapy: tipping the balance between the immune stimulatory and inhibitory effectsFront Immunol201458324624132
   PubMed Web of Science ®Google Scholar
• KaczanowskaSJosephAMDavilaETLR agonists: our best frenemy in cancer immunotherapyJ Leukoc Biol201393684786323475577
   PubMed Web of Science ®Google Scholar
• VacchelliEEggermontASautès-FridmanCTrial Watch: Toll-like receptor agonists for cancer therapyOncoimmunology201428e2523824083080
   PubMed Web of Science ®Google Scholar
• VacchelliEGalluzziLEggermontATrial watch: FDA-approved Toll-like receptor agonists for cancer therapyOncoimmunology20121689490723162757
   PubMed Web of Science ®Google Scholar
• StephensonRMLimCMMatthewsMDietschGHershbergRFerrisRLTLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cellsCancer Immunol Immunother20136281347135723685782
   PubMed Web of Science ®Google Scholar
• Ming LimCStephensonRSalazarAMFerrisRLTLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cellsOncoimmunology201326e2467723894722
   PubMed Web of Science ®Google Scholar
• RodaJMPariharRCarsonWE3rdCpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cellsJ Immunol200517531619162716034101
   PubMed Web of Science ®Google Scholar
• SommarivaMde CesareMMeiniAHigh efficacy of CpG-ODN, cetuximab and cisplatin combination for very advanced ovarian xenograft tumorsJ Transl Med2013112523360557
   PubMed Web of Science ®Google Scholar
• MogaEAlvarezECantóENK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphomaExp Hematol2008361697717959301
   PubMed Web of Science ®Google Scholar
• WangHRayburnERWangWKandimallaERAgrawalSZhangRImmunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapyMol Cancer Ther2006582106211416928832
   PubMed Web of Science ®Google Scholar
• WooldridgeJEBallasZKriegAMWeinerGJImmunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphomaBlood1997898299429989108420
   PubMed Web of Science ®Google Scholar
• BettingDJYamadaREKafiKSaidJvan RooijenNTimmermanJMIntratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphomaJ Immunother200932662263119483647
   PubMed Web of Science ®Google Scholar
• van OjikHHBevaartLDahleCECpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populationsCancer Res200363175595560014500400
   PubMed Web of Science ®Google Scholar
• LinWVoskensCJZhangXFc-dependent expression of CD137 on human NK cells: insights into “agonistic” effects of anti-CD137 monoclonal antibodiesBlood2008112369970718519814
   PubMed Web of Science ®Google Scholar
• MeleroIShufordWWNewbySAMonoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumorsNat Med1997366826859176498
   PubMed Web of Science ®Google Scholar
• WilcoxRAFliesDBZhuGProvision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumorsJ Clin Invest2002109565165911877473
   PubMed Web of Science ®Google Scholar
• KohrtHEHouotRGoldsteinMJCD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodiesBlood201111782423243221193697
   PubMed Web of Science ®Google Scholar
• KohrtHEHouotRWeiskopfKStimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancerJ Clin Invest201212231066107522326955
   PubMed Web of Science ®Google Scholar
• KohrtHEColevasADHouotRTargeting CD137 enhances the efficacy of cetuximabJ Clin Invest201412462668268224837434
   PubMed Web of Science ®Google Scholar
• VilchesCParhamPKIR: diverse, rapidly evolving receptors of innate and adaptive immunityAnnu Rev Immunol20022021725111861603
   PubMed Web of Science ®Google Scholar
• KohCYBlazarBRGeorgeTAugmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivoBlood200197103132313711342440
   PubMed Web of Science ®Google Scholar
• RomagnéFAndréPSpeePPreclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cellsBlood2009114132667267719553639
   PubMed Web of Science ®Google Scholar
• BensonDMJrHofmeisterCCPadmanabhanSA phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myelomaBlood11222012120224324433323033266
   PubMed Web of Science ®Google Scholar
• VeyNBourhisJHBoisselNA phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remissionBlood2012120224317432323002117
   PubMed Web of Science ®Google Scholar
• KeirMEButteMJFreemanGJSharpeAHPD-1 and its ligands in tolerance and immunityAnnu Rev Immunol20082667770418173375
   PubMed Web of Science ®Google Scholar
• ZitvogelLKroemerGTargeting PD-1/PD-L1 interactions for cancer immunotherapyOncoimmunology2012181223122523243584
   PubMed Web of Science ®Google Scholar
• TermeMUllrichEAymericLCancer-induced immunosuppression: IL-18-elicited immunoablative NK cellsCancer Res201272112757276722427351
   PubMed Web of Science ®Google Scholar
• BensonDMJrBakanCEMishraAThe PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibodyBlood2010116132286229420460501
   PubMed Web of Science ®Google Scholar
• RobertCRibasAWolchokJDAnti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialLancet201438499481109111725034862
   PubMed Web of Science ®Google Scholar
• NocentiniGRiccardiCGITR: a modulator of immune response and inflammationAdv Exp Med Biol200964715617319760073
   PubMed Web of Science ®Google Scholar
• PlackeTKoppHGSalihHRGlucocorticoid-induced TNFR-related (GITR) protein and its ligand in antitumor immunity: functional role and therapeutic modulationClin Dev Immunol2010201023908320936139
   PubMedGoogle Scholar
• BaltzKMKruschMBringmannACancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactionsFASEB J200721102442245417360848
   PubMed Web of Science ®Google Scholar